Corrigendum to “Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers” [Neurobiol. Dis. 83 (2015) 115–121](S0969996115300322)(10.1016/j.nbd.2015.08.011);Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers

Neurobiology of Disease

Volumn 83, Issue , 2015, Pages 115-121

  Politis, Marios ^a,b   Lahiri, Nayana ^c   Niccolini, Flavia ^a,b   Su, Paul ^b   Wu, Kit ^b   Giannetti, Paolo ^b   Scahill, Rachael I ^c   Turkheimer, Federico E ^a   Tabrizi, Sarah J ^c   Piccini, Paola ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Huntington's disease; Microglia; MRI; Peripheral inflammation; PET

Indexed keywords

CYTOKINE; HUNTINGTIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; TUMOR NECROSIS FACTOR ALPHA; (R)-(11C)1-(2-CHLOROPHENYL)-N-METHYL-N-(1-METHYLPROPYL)-3-ISOQUINOLINECARBOXAMIDE; AMIDE; AUTACOID; ISOQUINOLINE DERIVATIVE; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CAUDATE NUCLEUS; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; FEMALE; GLOBUS PALLIDUS; HETEROZYGOTE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNOPATHOLOGY; INNATE IMMUNITY; MALE; MICROGLIA; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUTAMEN; SOMATOSENSORY CORTEX; THALAMUS; VENTRAL STRIATUM; BLOOD; BRAIN; DIAGNOSTIC IMAGING; ENCEPHALITIS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM;

ADULT; AMIDES; BRAIN; CYTOKINES; ENCEPHALITIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HUNTINGTON DISEASE; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; ISOQUINOLINES; MALE; MICROGLIA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84941213597     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2016.12.003     Document Type: Erratum

References (60)

1. Anderson A.N., Pavese N., Edison P., Tai Y.F., Hammers A., Gerhard A., Brooks D.J., Turkheimer F.E. A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195. NeuroImage 2007, 36:28-37.
2. Huntington's Disease 2002, 558. Oxford University Press, Oxford. G. Bates, P.S.L. Harper, L. Jones (Eds.).
3. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat Methodol. 1995, 57:289-300.
4. Björkqvist M., Wild E.J., Thiele J., Silvestroni A., Andre R., Lahiri N., et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 2008, 205:1869-1877.
5. Boellaard R., Turkheimer F.E., Hinz R., Schuitemaker A., Scheltens P., van Berckel B.N.M., et al. Performance of a modified supervised cluster algorithm for extracting reference region input functions from (R)-[C-11]PK11195 brain PET studies. IEEE Nuclear Science Symposium/Medical Imaging Conference 2009, 4666-4668.
6. Chang K.H., Wu Y.R., Chen Y.C., Chen C.M. Plasma inflammatory biomarkers for Huntington's disease patients and mouse model. Brain Behav. Immun. 2015, 44:121-127.
7. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 2000, 6:797-801.
8. Craufurd D., Thompson J.C., Snowden J.S. Behavioral changes in Huntington disease. Neuropsychiatry Neuropsychol. Behav. Neurol. 2001, 14:219-226.
9. Crocker S.F., Costain W.J., Robertson H.A. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations. Brain Res. 2006, 1088:176-186.
10. Crotti A., Benner C., Kerman B.E., Gosselin D., Lagier-Tourenne C., Zuccato C., et al. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci. 2014, 17:513-521.
11. Dagher A., Gunn R.N., Lockwood G., Cunningham V.J., Grasby P.M., Brooks D.J. Measuring neurotransmitter release with PET: methodological issues. Quantitative Functional Brain Imaging With Positron Emission Tomography 1998, Academic, London. R.E. Carson, M.E. Daube-Witherspoon, P. Herscovitch (Eds.).
12. Ferrante R.J., Gutekunst C.A., Persichetti F., McNeil S.M., Kowall N.W., Gusella J.F., et al. Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J. Neurosci. 1997, 17:3052-3063.
13. Friedlander R.M., Gagliardini V., Rotello R.J., Yuan J. Functional role of interleukin 1 beta (IL-1beta) in IL-1 beta-converting enzyme-mediated apoptosis. J. Exp. Med. 1996, 184:717-724.
14. Gousias I.S., Rueckert D., Heckemann R.A., Dyet L.E., Boardman J.P., Edwards A.D., et al. Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest. NeuroImage 2008, 40:672-684.
15. Gunn R.N., Lammertsma A.A., Hume S.P., Cunningham V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage 1997, 6:279-287.
16. Hammers A., Allom R., Koepp M.J., Free S.L., Myers R., Lemieux L., et al. Three dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum. Brain Mapp. 2003, 19:224-247.
17. Hammers A., Heckemann R., Koepp M.J., Duncan J.S., Hajnal J.V., Rueckert D., et al. Automatic detection and quantification of hippocampal atrophy on MRI in temporal lobe epilepsy: a proof-of-principle study. Neuroimage. 2007, 36:38-47.
18. Heckemann R.A., Hajnal J.V., Aljabar P., Rueckert D., Hammers A. Automatic anatomical brain MRI segmentation combining label propagation and decision fusion. NeuroImage 2006, 33:115-126.
19. Heckemann R.A., Keihaninejad S., Aljabar P., Rueckert D., Hajnal J.V., Hammers A., Alzheimer's Disease Neuroimaging Initiative Improving intersubject image registration using tissue-class information benefits robustness and accuracy of multi-atlas based anatomical segmentation. NeuroImage 2010, 51:221-227.
20. Hersch S.M., Gevorkian S., Marder K., Moskowitz C., Feigin A., Cox M., et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006, 66:250-252.
21. Huntington Study Group Unified Huntington's disease rating scale: reliability and consistency. Mov. Disord. 1996, 11:136-142.
22. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
23. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
24. Kemp B.J., Kim C., Williams J.J., Ganin A., Lowe V.J., National Electrical Manufacturers Association (NEMA) NEMA NU 2-2001 performance measurements of an LYSO-based PET/CT system in 2D and 3D acquisition modes. J. Nucl. Med. 2006, 47:1960-1967.
25. Khoshnan A., Ko J., Watkin E.E., Paige L.A., Reinhart P.H., Patterson P.H. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J. Neurosci. 2004, 24:7999-8008.
26. Knudsen L.S., Christensen I.J., Lottenburger T., Svendsen M.N., Nielsen H.J., Nielsen L., et al. Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers 2008, 13:59-78.
27. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19:312-318.
28. Kwan W., Träger U., Davalos D., Chou A., Bouchard J., Andre R., et al. Mutant huntingtin impairs immune cell migration in Huntington disease. J. Clin. Invest. 2012, 122:4737-4747.
29. Langbehn D.R., Brinkman R.R., Falush D., Paulsen J.S., Hayden M.R., International Huntington's Disease Collaborative Group A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin. Genet. 2004, 65:267-277.
30. McColl J.H., Holmes A.P., Ford I. Statistical methods in neuroimaging with particular application to emission tomography. Stat. Methods Med. Res. 1994, 3:63-86.
31. Melton L.M., Keith A.B., Davis S., Oakley A.E., Edwardson J.A., Morris C.M. Chronic glial activation, neurodegeneration, and APP immunoreactive deposits following acute administration of double-stranded RNA. Glia 2003, 44:1-12.
32. Montgomery A.J., Thielemans K., Mehta M.A., Turkheimer F., Mustafovic S., Grasby P.M. Correction of head movement on PET studies: comparison of methods. J. Nucl. Med. 2006, 47:1936-1944.
33. Nakanishi H. Microglial functions and proteases. Mol. Neurobiol. 2003, 27:163-176.
34. Ona V.O., Li M., Vonsattel J.P., Andrews L.J., Khan S.Q., Chung W.M., et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999, 399:263-267.
35. Pavese N., Gerhard A., Tai Y.F., Ho A.K., Turkheimer F., Barker R.A., et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006, 66:1638-1643.
36. Penney J.B., Vonsattel J.P., MacDonald M.E., Gusella J.F., Myers R.H. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol. 1997, 41:689-692.
37. Politis M., Pavese N., Tai Y.F., Tabrizi S.J., Barker R.A., Piccini P. Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain 2008, 131:2860-2869.
38. Politis M., Pavese N., Tai Y.F., Kiferle L., Mason S.L., Brooks D.J., et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum. Brain Mapp. 2011, 32:258-270.
39. Quarantelli M., Berkouk K., Prinster A., Landeau B., Svarer C., Balkay L., et al. Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J. Nucl. Med. 2004, 45:192-201.
40. Reilmann R., Bohlen S., Klopstock T., Bender A., Weindl A., Saemann P., et al. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease. Mov. Disord. 2010, 25:2195-2202.
41. Reilmann R., Bohlen S., Kirsten F., Ringelstein E.B., Lange H.W. Assessment of involuntary choreatic movements in Huntington's disease-toward objective and quantitative measures. Mov. Disord. 2011, 26:2267-2273.
42. Riess O., Noerremoelle A., Soerensen S.A., Epplen J.T. Improved PCR conditions for the stretch of (CAG)n repeats causing Huntington's disease. Hum. Mol. Genet. 1993, 2:637.
43. Silvestroni A., Faull R.L., Strand A.D., Möller T. Distinct neuroinflammatory profile in postmortem human Huntington's disease. Neuroreport 2009, 20:1098-1103.
44. Smith A. The symbol-digit modalities test: a neuropsychologic test of learning and other cerebral disorders. Learning disorders 1935, 83-91. J. Helmuth (Ed.).
45. Stroop R.J. Studies of interference in serial verbal reactions. J. Exp. Psychol. 1935, 18:643-662.
46. Studholme C., Hill D.L., Hawkes D.J. Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med. Phys. 1997, 24:25-35.
47. Tabrizi S.J., Langbehn D.R., Leavitt B.R., Roos R.A., Durr A., Craufurd D., TRACK-HD investigators, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009, 8:791-801.
48. Tabrizi S.J., Scahill R.I., Owen G., Durr A., Leavitt B.R., Roos R.A., TRACK-HD Investigators, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013, 12:637-649.
49. Tai Y.F., Pavese N., Gerhard A., Tabrizi S.J., Barker R.A., Brooks D.J., et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007, 130:1759-1766.
50. Tomasi G., Edison P., Bertoldo A., Roncaroli F., Singh P., Gerhard A., et al. Novel reference region model reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimer's disease. J. Nucl. Med. 2008, 49:1249-1256.
51. Träger U., Andre R., Lahiri N., Magnusson-Lind A., Weiss A., Grueninger S., et al. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. Brain 2014, 137:819-833.
52. Trottier Y., Devys D., Imbert G., Saudou F., An I., Lutz Y., et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat. Genet. 1995, 10:104-110.
53. Troy C.M., Stefanis L., Prochiantz A., Greene L.A., Shelanski M.L. The contrasting roles of ICE family proteases and interleukin-1beta in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:5635-5640.
54. Turkheimer F.E., Brett M., Visvikis D., Cunningham V.J. Multiresolution analysis of emission tomography images in the wavelet domain. J. Cereb. Blood Flow Metab. 1999, 19:1189-1208.
55. Turkheimer F.E., Edison P., Pavese N., Roncaroli F., Anderson A.N., Hammers A., et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J. Nucl. Med. 2007, 48:158-167.
56. Vgontzas A.N., Zoumakis E., Bixler E.O., Lin H.M., Follett H., Kales A., Chrousos G.P. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J. Clin. Endocrinol. Metab. 2004, 89:2119-2126.
57. Vgontzas A., Bixler E., Lin H., Prolo P., Trakada G., Chrousos G. IL-6 and its circardian secretion in humans. Neuroimmunomodulation 2005, 12:131-140.
58. Viviani B., Bartesaghi S., Gardoni F., Vezzani A., Behrens M.M., Bartfai T., et al. Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J. Neurosci. 2003, 23:8692-8700.
59. Warner J.P., Barron L.H., Brock D.J. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol. Cell. Probes 1993, 7:235-239.
60. Yaqub M., van Berckel B.N., Schuitemaker A., Hinz R., Turkheimer F.E., Tomasi G., et al. Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[(11)C]PK11195 brain PET studies. J. Cereb. Blood Flow Metab. 2012, 32:1600-1608.